glp-1 amgen Before this week hasn't been able to generate excitement for its GLP-1, says Jim Cramer Beyond GLP-1: the next wave

doi: 10.1053/j.gastro.2004.04.063 27 SmitsMMTonneijckLMuskietMHAKramerMHHCahenDLvan RaalteDH

1 The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsA Long-Term Evaluation), a large double-blind, placebo-controlled trial, recently demonstrated that liraglutide added to standard therapy for a relatively short period of time (3.5-5 years) had a significant reduction in cardiovas-cular events and mortality compared to placebo in high-risk patients (hazard ratio [HR], 0.87

Yes, for optimal results, it is generally recommended to combine GLP-1 therapy with lifestyle changes, such as a healthy diet and regular physical activity

The FDA currently classifies GLP-1 receptor agonists as class C for use in pregnancy, and these medications are not recommended during pregnancy